Growth Hormone and Heart Failure: Implications for Patient Stratification, Prognosis, and Precision Medicine
Author Information
Author(s): Theodorakis Nikolaos, Kreouzi Magdalini, Hitas Christos, Anagnostou Dimitrios, Nikolaou Maria
Primary Institution: NT-CardioMetabolics, Clinic for Metabolism and Athletic Performance, Greece
Hypothesis
How can growth hormone contribute to personalized care and improve patient stratification in heart failure?
Conclusion
Growth hormone therapy shows promise for improving cardiac function and exercise capacity in heart failure patients, but evidence remains mixed.
Supporting Evidence
- GH therapy can improve left ventricular ejection fraction in heart failure patients.
- Patients with growth hormone deficiency may benefit the most from GH therapy.
- Improvements in exercise capacity were observed in several studies following GH treatment.
- GH therapy has shown mixed results, with some studies reporting no significant benefits.
Takeaway
This study looks at how growth hormone can help people with heart failure feel better and live longer, but not everyone benefits the same way.
Methodology
A comprehensive literature review of randomized controlled trials was conducted using PubMed, focusing on studies involving growth hormone therapy in heart failure.
Potential Biases
Potential bias due to the heterogeneity of heart failure etiology and patient selection criteria.
Limitations
Small sample sizes and variability in study designs limit the generalizability of the findings.
Participant Demographics
Participants included heart failure patients with varying degrees of left ventricular ejection fraction and hormonal deficiencies.
Statistical Information
P-Value
p = 0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website